Last updated: 2026-09-09 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Harvard Bioscience Inc. (HBIO) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NASDAQ. The stock is currently priced at $8.10, with a market capitalization of $36.51M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.76 to $9.40. This page covers its latest market performance, valuation, price trends and company information.
$36.51M | |
$7.90 | |
$111.00 | |
$2.81 | |
$8.02 | |
11.94K | |
18.07K | |
-- | |
$9.40 | |
$3.76 | |
-- | |
-- |
Harvard Bioscience Inc. (HBIO) last closed at $8.02 as of 2026-09-08 23:31:00, unchanged from the previous close of $8.02.
During the latest regular trading session, HBIO traded between $2.81 and $111.00, with a volume of 11.94K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Harvard Bioscience Inc. (HBIO) moved from $7.90 to $8.10, representing a gain of 2.48% ($0.20).
The stock traded between $7.67 and $8.40 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 24.49 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 76.9%
HBIO is currently trading at $8.10, placing it 76.9% of the way from its 52-week low of $3.76 to its 52-week high of $9.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 339 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harvard Bioscience Inc. (HBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.